CAMBRIDGE, Mass. — Abselion, a life sciences technology company focused on biomolecule quantification, has appointed Dale Gordon as Chair of its Board of Directors as the company advances its commercial strategy and international growth.
The appointment comes as Abselion builds on the recent establishment of its U.S. subsidiary and expands global engagement around its Amperia protein quantification system. The company said Gordon’s addition strengthens board-level expertise and governance as it targets long-term growth across academic, biotech, and pharmaceutical markets.
As Chair, Gordon will help guide strategy and ensure sustainable value creation as demand for Abselion’s technology grows across biologics characterization, development, and manufacturing workflows.
“Dale is renowned for his expertise in bioprocessing and strategic leadership. His appointment will strengthen our ability to make clear, confident decisions as we continue to build the business for long-term impact,” said Dr Ruizhi Wang, CEO and Founder, Abselion.
Gordon brings more than 30 years of experience in the life sciences sector, including leadership roles in bioprocessing, company building, and corporate governance. He most recently served as CEO of Mirus Bio, where he led the company through a period of significant growth and strategic development. He has also held CEO roles at Gemini Bio and leadership positions at GE Life Sciences, now Cytiva, and Merck Millipore.
Abselion said Gordon’s experience working with growth-stage companies will support its transition from early adoption to broader commercial deployment, providing strategic oversight and strengthening decision-making processes.
“Dale is renowned for his expertise in bioprocessing and strategic leadership. His appointment will strengthen our ability to make clear, confident decisions as we continue to build the business for long-term impact,” Wang added.
Wang noted that Gordon joins at a pivotal stage as the company shifts toward execution, with increasing commercial activity and expanding international presence.
“Dale joins us at a point where the company is moving from early momentum into a more execution-focused phase, with growing commercial engagement and increasing international activity. His experience in guiding life sciences companies through this transition will be an invaluable asset as we continue our global expansion,” Wang said.
The company also acknowledged outgoing Chair Simon Douglas, who is stepping down after more than four years in the role.
“We’d also like to express our sincere thanks to Simon for his insightful contribution and support during an important period in the company’s initial development,” Wang said.
Gordon said he sees significant opportunity ahead for the company as it translates its scientific capabilities into real-world applications.
“Abselion has built strong scientific foundations alongside a clear focus on addressing practical challenges in cell and gene therapy and biopharma development and production workflows. I see a significant opportunity in how the company is translating that work into real-world use,” Gordon said.
“I’m looking forward to working with the Board to support the company’s continued growth, strengthen its commercial direction, and help guide the next phase of its journey.”
